Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation ...
Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL Continuing to advance next-generation modular bioconjugation platform; IND...
Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting Presented preliminary findings on VIP152 in gynecologic...
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented for...
Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101 Preliminary findings in gynecologic malignancies will be presented as...
PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet...
VIP236 is a first-in-class anticancer agent, optimized using Vincerx’s proprietary modular bioconjugation platform to target aggressive tumors VIP236...
PALO ALTO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet...
VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx...
PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet...